Fairway began its business model by acquiring a breakthrough technology (optoaccoustic imaging) with pivotal cancer and cardiovascular applications that originated from the M.D. Anderson Cancer Center.  Fairway applied for and received approximately $7.4 million in Federal NIH grants to support the commercialization process. In May 2006, after establishing a standalone company (Seno Medical www.senomedical.com) and recruiting a dedicated management team, Fairway executed a 10-year exclusive design and development agreement with Seno. As of January 2009, Seno has successfully raised $9 million and is engaged in raising an additional $15 million. Fairway currently owns approximately 20% of Seno. Successful Fairway team experience has validated Fairway’s business model and inspired it to reproduce the success. Since 2006, the following companies have been added to Fairway portfolio and are in different stages of development.

In 2007, Fairway signed an exclusive manufacturing agreement with Monebo Technologies (www.monebo.com). Subsequently, Cormedics (intrapericardial drug delivery technologies www.cormedicscorp.com) was added to the portfolio. 

In 2008, Fairway added TraumaTec (brain cooling device www.traumatec.com) and Endothelix (vascular screening test www.endothelix.com).  

In 2009, through an equity transfer merger with In3 Ventures, ThermaRx (urinary hesitancy treatment www.thermarx.com), IC Therapeutics (ischemic conditioning therapy www.ictherapeutics.com) and CardioNexus (cardiovascular imaging -under development) have been added to Fairway Portfolio Companies.

Cormedics Corporation is a life sciences company focused on developing novel technologies that selectively treat the entire heart with drug, cell, gene, and device therapies by introducing them into the pericardial space.

Endothelix, Inc. is a cardiovascular device company based in Houston, Texas and is focused on non-invasive vascular function measurement.

The mission of IC Therapeutics is to develop and market medical devices that bring the remarkable therapeutic benefits of ischemic conditioning to clinical practice and health consumers.

MicroMedCo Corp. sells advanced technology products developed by Edwards NanoScience, Inc. to medical institutions to protect against virulent pathogens such as the MRSA “Superbug”, Avian Virus, SARS, Tuberculosis, and Mold-Allergen contamination.

Monebo Technologies is dedicated to providing patients, physicians and partner companies with exceptional technology designed to increase the quality and efficiency of cardiac care.

Seno Medical, Inc. was formed to commercialize a new modality in cancer screening and diagnosis: opto-acoustic imaging. Unlike most screening techniques, which rely on anatomical imaging, Seno's goal is to bring functional imaging that can detect angiogenesis to the marketplace.

ThermaRx Inc. is a medical device company based in Houston, Texas focused on developing and marketing innovative products that provide novel therapeutic applications of heat to improve a variety of health conditions.

TraumaTec's vision is to reduce post injury and secondary brain injury through the use of innovative, FDA-registered therapeutic cooling technologies.